Premium
Human‐induced pluripotent stem cell‐derived blood products: state of the art and future directions
Author(s) -
Hansen Marten,
von Lindern Marieke,
van den Akker Emile,
Varga Eszter
Publication year - 2019
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.13599
Subject(s) - induced pluripotent stem cell , haematopoiesis , stem cell , blood cell , hematopoietic stem cell transplantation , in vitro , immunology , medicine , cancer research , microbiology and biotechnology , biology , embryonic stem cell , biochemistry , gene
In vitro cultured blood cells for transfusion purposes provide a safe alternative to donor blood, particularly for patients who require recurrent transfusions, and can be used as carriers of therapeutic molecules. In vitro derivation of hematopoietic cell types from human‐induced pluripotent stem cells ( iPSC s) allows for a constant, well‐defined production pipeline for such advanced therapeutic and medicinal products. Application of selected iPSC ‐derived hematopoietic stem cells and hematopoietic effector cells in transplantation/transfusions would avoid the risk of alloimmunization and blood‐borne diseases, as well as enable the production of enhanced blood cells expressing molecules that enforce blood cell function or endow novel therapeutic properties. Here, we discuss the state of the art approaches to produce erythroid, megakaryoid and myeloid cells from iPSC s and the biological and technical hurdles that we need to overcome prior to therapeutic application.